News

News 04.02.2021 Zurich-Schlieren, Switzerland, February 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced results from a study conducted at Spiez Laboratory. The study assessed leading SARS-CoV-2 anti-infective molecules, including...

News 14.01.2021 Beijing, CN, Henan, CN and Zurich-Schlieren, CH, January 14, 2021. Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix® prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics. The leading...

News 07.01.2021 Zurich-Schlieren, Switzerland, January 07, 2021 - Proteomedix, the Swiss cancer diagnostics company, announced today that the results of PROPOSe, a prospective multicenter study of Proclarix® in clinical routine use, were published in European Urology Oncology1). Prostate specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or...

News 04.01.2021 OAKLAND, N.J., Dec. 29, 2020 /PRNewswire/ -- Collagen Matrix, Inc., a global leader in regenerative, collagen-based, xenograft-derived medical devices, and portfolio company of Linden Capital Partners ("Linden"), announced today the acquisition of Sunstar's Degradable Solutions division (the "Company"), including its GUIDOR® branded line of resorbable synthetic medical implants. Founded in 1999, Degradable Solutions AG, is...

News 17.12.2020 Zurich-Schlieren, Switzerland, December 17, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio...